Kallikrein activates prothrombin

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 1, 2008, Pages 97-98

  Stief, Thomas W ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Chromogenic test; Contact phase; Intrinsic hemostasis; Kallikrein; Prothrombin; Thrombin

Indexed keywords

ALBUMIN; ARGININE; KALLIKREIN; PHOSPHATE BUFFERED SALINE; PROTHROMBIN; THROMBIN;

ALBUMIN BLOOD LEVEL; ARTICLE; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; NORMAL HUMAN; PH; PRIORITY JOURNAL;

BLOOD COAGULATION; CALCIUM; HEMOSTASIS; HUMANS; INDICATORS AND REAGENTS; KALLIKREINS; METHODS; PROTHROMBIN; THROMBIN;

EID: 37549020755     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607308036     Document Type: Article

References (16)

1. Saito H., Goldsmith G., Ratnoff OD Fletcher factor activity in plasmas of various species. Proc Soc Exp Biol Med. 1974 ; 147: 519-523.
2. Becker CG, Wagner M., Kaplan AP, et al. Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin. J Clin Invest. 1985 ; 76: 413-419.
3. Powers JC, Kam CM, Narasimhan L., Oleksyszyn J., Hernandez MA, Ueda T. Mechanism-based isocoumarin inhibitors for serine proteases: use of active site structure and substrate specificity in inhibitor design. J Cell Biochem. 1989 ; 39: 33-46.
4. Naess F., Roeise O., Johansen HT, Stadaas JO, Aasen AO Hemodynamic and proteolytic effects of intravenous injection of purified human plasma kallikrein. Am J Physiol. 1992 ; 263: H405 - H409.
5. Sriskandan S., Cohen J. Kallikrein-kinin system activation in streptococcal toxic shock syndrome. Clin Infect Dis. 2000 ; 30: 961-962.
6. Yamaguchi K., Majima M., Katori M., Kakita A., Sugimoto K. Preferential consumption of coagulation factors I, V, and VIII in rat endotoxemia. Shock. 2000 ; 14: 535-543.
7. Sharma JN Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol. 2003 ; 43: 1187-1195.
8. Shariat-Madar Z., Schmaier AH The plasma kallikrein/ kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res. 2004 ; 10: 3-13.
9. Colman RW The contact system and angiogenesis: potential for therapeutic control of malignancy. Semin Thromb Hemost. 2004 ; 30: 45-61.
10. Domenico R. Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies. Curr Pharm Des. 2004 ; 10: 1667-1676.
11. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci. 2004 ; 41: 265-312.
12. Borgono CA, Michael IP, Diamandis EP Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004 ; 2: 257-280.
13. Marcondes S., Antunes E. The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Curr Med Chem Cardiovasc Hematol Agents. 2005 ; 3: 33-44.
14. Ichinose A., Fujikawa K., Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem. 1986 ; 261: 3486-3489.
15. Stief TW Specific determination of plasmatic thrombin. Clin Appl Thromb Hemost. 2006 ; 12: 324-329.
16. Baskova IP, Tiero A., Krizhevskaia IuV, Iarovaia GA, Mirkamalova EG. Prothrombin-substrate for blood plasma kallikrein and factor XIIa. Biull Eksp Biol Med. 1983 ; 96: 13-16.